Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Service Agreement with StarFish Medical (“StarFish”), Canada’s largest medical device design, development and contract manufacturing company, to assist in the design and development of the MagSense instrument platform for clinical applications.
View the ASX announcement, “Imagion Biosystems Initiates MagSense Instrument Development.”
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has